# Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors

> **NCT04602702** · — · UNKNOWN · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 50 (estimated)

## Conditions studied

- Kidney Neoplasm
- Carcinoma, Renal Cell
- Metastatic Solid Tumor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04602702
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602702, "Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04602702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*